In September 2008, the NIH launched a Hepatitis B Research Network (http://www.hepbnet.org) comprised of 29 clinical centers (adult and pediatric), a data coordinating center, and an immunology laboratory. The University of Michigan is one of the clinical centers and Dr. Anna Lok chairs the network's steering committee.
This network conducts observational studies as well as clinical studies of new treatment strategies.
To study the pattern of hepatitis B in North America and the rates of transition through different phases of chronic HBV infection.
Principal investigator: Anna Lok, MD firstname.lastname@example.org
Contact person: Sravanthi Kaza: (734) 615-3853 or email@example.com
To compare the long-term efficacy of initial treatment with combination therapy consisting of peginterferon alfa-2a plus tenofovir DF versus tenofovir DF monotherapy.
This is a randomized (1:1) trial comparing
Note: The cost of medications, clinical evaluations, and tests associated with the study will be covered.
Principal investigator: Anna Lok, MD firstname.lastname@example.orgContact person: Sravanthi Kaza: (734) 615-3853 or email@example.com